Key Takeaways Novo Nordisk gains FDA approval for Wegovy HD, showing 21% average weight loss in trials.NVO's obesity drug lineup may enhance competitiveness against Eli Lilly's Zepbound. Healthcare ETFs like OZEM offer diversified exposure to obesity drug market growth. The FDA recently approved higher-dose version of Novo Nordisk’s (NVO) obesity drug Wegovy, further expanding the drug giant’s footprint in the rapidly growing and fiercely competitive weight-loss market. Announced on March 19, 2026, the appr ...